Skip to content

URMC Response to CrowdStrike Software Issue

Saturday, July 20: All UR Medicine facilities are open as scheduled and providing safe patient care, with a goal to return all clinical services to full efficiency by early next week.

Patients: click here for more information. Faculty/Staff: click here for information.

Scott J. Cameron, Ph.D., M.D.

Scott J. Cameron, Ph.D., M.D.


Connect with Scott J. Cameron, Ph.D., M.D.

About Me

Dr. Cameron trained initially as a pharmacologist at the University of Edinburgh in Scotland which is his home country. He completed postgraduate training in the same discipline at the University of Rochester, then postdoctoral fellowship training in clinical chemistry at the Johns Hopkins Hospital...
Dr. Cameron trained initially as a pharmacologist at the University of Edinburgh in Scotland which is his home country. He completed postgraduate training in the same discipline at the University of Rochester, then postdoctoral fellowship training in clinical chemistry at the Johns Hopkins Hospital, Department of Pathology, in Baltimore.

Dr. Cameron then qualified in medicine at Upstate Medical University in Syracuse, later serving as an internal medicine resident at the New York Presbyterian Hospital-Cornell in New York City. He finally completed a five-year integrated clinical and research fellowship in cardiology and vascular medicine at the University of Rochester. Dr. Cameron was mentored in platelet biology by Dr. Craig Morrell who is a national expert in this discipline. He initiated an innovative vascular assessment referral clinic for local optometrists called Vascular Assessment in Patients for Ocular Reasons (VAPOR). He was also the founding member of the University of Rochester Pulmonary Embolism Response Team (PERT). Dr. Cameron has a clinical and academic interest in thrombotic emergencies and presently serves on the University of Rochester faculty as a physician investigator. He serves as Associate Editor of Vascular Medicine, and he is on the editorial board of ATVB. He is a frequent peer reviewer for Circulation, Circulation Research, Journal of Clinical Investigation, American Journal of Medicine, Journal of Thrombosis and Thrombolysis, and the British Medical Journal. In addition, Dr. Cameron is a test writer for the American Board of Internal Medicine Cardiovascular Disease MOC and longitudinal assessment.

Dr. Cameron specializes in both cardiac and vascular disease with admitting privileges at Strong Memorial Hospital where he cares for patients in the Coronary Care Unit. He has documented COCATS Level II training in echocardiography, nuclear cardiology, and COCATS Level III training in vascular medicine. Dr. Cameron is board certified in Internal Medicine, Vascular Medicine, Vascular Ultrasound, and Cardiovascular Disease.

Faculty Appointments

Adjunct Assistant Professor - Department of Medicine, Cardiology (SMD)


Post-doctoral Training & Residency

University of Rochester School of Medicine
Postdoctoral Fellowship (Basic Research)
Laboratory of Dr. Craig Morrell

New York Presbyterian Hospital (Weill-Cornell)
Internship and Residency (Internal Medicine)

Johns Hopkins Hospital, Baltimore MD
Clinical Fellowship (Chemical Pathology/Clinical Chemistry) Division of Pathology

University of Rochester School of Medicine,
Clinical Fellowship (Cardiovascular Disease and Vascular Medicine)

Memorial Sloan Kettering Cancer Center Internship and Residency (Internal Medicine)

Clinical and Research Fellowship in Chemical Pathology (Clinical Chemistry) at the Johns Hopkins Hospital.


MD | SUNY Upstate Medical University. Medicine. 2009

PhD | University of Rochester School of Medicine & Dentistry. Pharmacology. 2003

MS | University of Rochester School of Medicine & Dentistry. Pharmacology. 2001

BSc (Hons) | UK-University of Edinburgh. Pharmacology. 1998


Outstanding Young Alumnus 2019 - Upstate Medical University. 2019 - 2019

K Award Grant. 2018

Resident Research Mentoring Award. 2018

URMC Quality and Safety Certificate of Recognition - Pulmonary Embolism Response Team. 2017

Fellow of the American College of Cardiology. 2016

Jay D. Coffman MD Young Investigator Award in Vascular Medicine (2nd Place). 2016

Fellow of the Society of Vascular Medicine. 2016

NIH K08 Career Development Award. 2016

Best of AHA Abstracts. 2015

Abstract and Travel Award, First Place. 2015

Abstract Merit Badge (top 20%). 2015

Abstract and Travel Award (top 10%). 2015

Platelet Colloquium Career Investigator Award. 2015

Society of Vascular Medicine Scholarship. 2014

Abstract Award (NY State), Second Place. 2014

Postdoctoral Research Award (1st place). 2013

NIH LRP (NHLBI). 2013 - 2019

Multiple "Strong Star" nominations and Hall of Fame citation from patients and colleagues for exceptional clinical care. 2011 - 2012

Hospitalist award for best resident (honorable mention). 2011

Herbert Lourie, MD Graduation Award for gentility, thoughtfulness, philanthropy, compassion, commitment to academic excellence.. 2009

Alpha Omega Alpha Research Award – First Place. 2008

American College of Physicians NY Upstate Scientific Conference: First Place. 2008

Arnold Gold Humanism Honor Society for excellence in humanistic clinical care, leadership, compassion and dedication to service.. 2008

Distinguished Abstract Award (top 25 out of 837 selected abstracts). 2005

Young Investigator's Award - awarded with distinction. 2005

Pathology Young Investigator's Award for excellence in basic research – highest scoring winner. 2005

Pathology Young Investigator's Award for excellence in clinical research. 2004

Dean's Award for the Most Innovative PhD Thesis. 2003


Our laboratory studies signal transduction pathways in the cardiovascular system as they relate to thrombotic and ischemic diseases. Our research focus is mostly basic and translational in nature. We are particularly interested in identifying existing and novel platelet signaling pathways in myoc...
Our laboratory studies signal transduction pathways in the cardiovascular system as they relate to thrombotic and ischemic diseases. Our research focus is mostly basic and translational in nature. We are particularly interested in identifying existing and novel platelet signaling pathways in myocardial ischemia and in peripheral vascular disorders such as advanced peripheral artery disease (PAD), chronic venous insufficiency (CVI), and aortic aneurysmal disease. An overarching theme of our laboratory is personalized medicine where we aim to better define platelet function in disease states, paying close attention to post-receptor signal transduction pathways.

Platelets are small anucleate blood particles which play an important role in thrombosis, hemostasis, and inflammation. When patients are treated with anti-platelet drugs, some do not derive expected benefits or they experience off-target adverse events. We have initiated several lines of investigation that show the megakaryocyte-derived platelet phenotype may be fundamentally different in various diseases.

Project 1: Using a murine model of myocardial infarction, we have shown that platelet RNA and the platelet proteome as well as platelet agonist responsiveness are different in the post-myocardial infarct environment. A career-development grant was awarded to study the role of ERK5 and related protein kinases in changing platelet function in ischemic disease. We began enrolling patients with ST-segment elevation myocardial infarction (STEMI) and non ST-segment elevation myocardial infarction (NSTEMI) in July of 2016 to study this phenomenon immediately when the patient arrives in the emergency department at Strong Memorial Hospital.

Project 2: Using a murine model of abdominal aortic aneurysm (AAA) and, along with our colleagues in vascular surgery and cardiac surgery at the University of Rochester, we are studying platelet function both as a consequence of aortic disease and in promoting aortic disease progression. We use genetic approaches to identify platelet targets useful in modulating vascular disease.

Project 3: Using a murine model of critical limb ischemia (CLI) and various models mimicking the human condition of hypoxia, we have identified two important signal transduction mechanisms which lead to dysregulated platelet behavior. This may in part explain why patients with PAD are predisposed to heart attack and stroke. We recently extended our studies to human platelets from PAD patients with our colleagues in vascular surgery at the University of Rochester and in the Department of Pathology at the Johns Hopkins Hospital.

Project 4: It is well-documented that patients who are exposed to inhaled pollutants are predisposed to adverse cardiovascular events. Using platelets taken from patients with acute myocardial infarction, we are working with our colleagues in environmental medicine and public health at the University of Rochester to study the role of particulate matter and environmental pollutants in changing platelet function and promoting thrombosis. These studies may reveal protective mechanisms that could be employed to prevent adverse cardiac events caused by pollutants.

Project 5: Using our existing database of patients with venous thromboembolism (VTE), we are studying various clinical and translational aspect of high risk pulmonary embolism locally and as part of the National Pulmonary Embolism Response Team (PERT) consortium.

We utilize contemporary cell biology, biochemistry, molecular biology, and animal models to address these questions. Our overall goal is to evaluate gaps in clinical care, identify viable signaling pathways in human tissue for drug intervention, and then finally to utilize animal models to test the working hypothesis. We are a friendly, collaborative laboratory with continuous federal funding from 2016-2026 with a keen interest in the career development of all laboratory members.


Journal Articles

Effect of platelet inhibitors on thrombus burden in patients with acute pulmonary embolism.

Van Galen J, Pava L, Wright C, Elbadawi A, Chaturvedi A, Cameron SJ.

Platelets. 2021; 32(1): 138-140.

The Effect of Aspirin on Short-term Outcomes in Hospitalized Patients with SARS-CoV-2

Sahai A, *Bhandari B, Koupenova M, Freedman J, *Godwin M, McIntyre M, Chung M, Iskander JP, Kamran H, Hariri E, Aggarwal A, Kalra A, Bartholomew JR, McCrae KR, Elbadawi A, Svensson LG, Kapadia S, Cameron SJ.

Vascular Medicine. 2021; .

Update on COVID-19 and Cardiovascular Disease: from Bench to Bedside

Chung MK, Zidar D, Bristow M, Cameron SJ, Chan T, Harding III CV, Kwon DH Singh T, Tilton J, Tsai EJ, Tucker NR, Barnard J, Loscalzo J.

Circulation Research. 2021; 128(8): 1214-1236.

Sex-specific platelet activation through Protease-Activated Receptors Reverses in Myocardial Infarction

Kim BS, Auerbach DA, Sadhra H, Godwin M, Bhandari R, Ling FS, Mohan A, Yule DI, Wagner II L, Rich DQ, Ture SK, Morrell CN, Timpanaro-Perrotta, Younis A, Goldenberg I, Cameron SJ.

Arterioscler Thromb Vasc Biol. 2021; 41(1): 390-400.

Incidence and Outcomes of Thrombotic Events in Symptomatic Patients with COVID-19

Elbadawi A, Eldendy IY, Sahai A, Bhandari R, McCarthy M, Gomes M, Bishop GJ, Bartholomew JR, Kapadia S, Cameron SJ.

Arterioscler Thromb Vasc Biol. 2021; 41(1): 545-547.

Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies

Xu S, Ilyas I,. Little PJ, Li H, Kamato D, Watts S, Ebong E, Cameron SJ, Stewart AG, Weng J.

Pharmacol Rev. 2021; 73(3): 924-967.

Keeping an eye on vascular disease.

Cameron SJ, Engel R.

Vascular Medicine. 2021; 26(3): 310-311.

Simultaneous Pulmonary Artery Pressure and Left Ventricle Stroke Volume Assessment Predicts Adverse Events in Patients with Pulmonary Embolism.

Kamran H, Hariri E, Iskandar JP, Sahai A, Haddadin I, Campbell J, Harb SC, Delehanty JM, Bartholomew JR, Heresi G, Cameron SJ.

J American Heart Association. 2021; .

SARS-CoV-2 Initiates Programmed Cell Death in Platelets.

Koupenova M, Corkrey HA, Vitseva O, Tanriverdi K, Somasundaran M, Liu P, Soofi S, Bhandari R, Godwin M, Parsi KM, Cousineau A, Maehr R, Wang J, Cameron SJ, Rade JJ, Finberg RW, Freedman JE.

Circulation Research. 2021; .

Cardiac Biomarkers and Right Ventricular Dysfunction are Simple and Sufficient Criteria for Risk Stratification by a Pulmonary Embolism Response Team

Chen YL, Wright C, Pietropaoli AP, Elbadawi A, Delehanty, J Barrus B, Gosev G, Trawick D, Patel P, and Cameron SJ.

Journal of Thrombosis and Thrombolysis. 2020; 49(1): 34-41.

Fibrosis, Thrombosis, and Dacrocytosis: An Unusual Case of Male Systemic Lupus Erythematosus

Wu MQ, Preslar M, Katerji H, Palma C, Cameron SJ.

American Journal of Medicine. 2020; .

Effect of metabolic syndrome on mean pulmonary arterial pressures in patients with acute pulmonary embolism treated with catheter-directed thrombolysis.

Stewart LK, Beam DM, Casciani T, Cameron SJ, Kline JA.

Int J Cardiol. 2020; .

A survey of commonly misunderstood vascular medicine physical exam findings among medical trainees

Kamran H, Hornacek D, Mix M, Wright C, Cameron SJ.

Vascular Medicine. 2020; .

Surgical Pulmonary Embolectomy with No Systemic Anticoagulation for Patient with Recent Stroke.

Ayers B, Wood K, Cameron SJ, Marinescu M, Bjelic M, Barrus B and Gosev I.

Annals of Thoracic Surgery. 2020; .

Anti-platelet Medications Protect against Aortic Dissection and Rupture in Patients with Abdominal Aortic Aneurysms.

Elbadawi A, Omer M, Ogunbayo G, Owens III, AP, Mix D, Lyden SP and Cameron SJ.

Journal of the American College of Cardiology. 2020; 7(75): 1609-1610.

The choline transporter Slc44a2 controls platelet activation and thrombosis by regulating mitochondrial function.

Bennett J, Mastrangelo M, Ture S, Smith C, Loelius S, Berg R, Shi X, Burke R, Spinelli S, Cameron SJ, Carey T, Brookes P, Gerszten R, Sabater-Lleal M, De Vries P, Huffman J, Smith N, Morrell C, and Lowenstein CJ.

Nature Communications. 2020; .

SARS-CoV-2 and ACE2: The Biology and Clinical Data Behind the ARB and ACEI Controversy.

Chung MK, Karnik S, Saef J, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB, Mehta N, Cameron SJ, McCrae KR, Schmaier, AH, Smith JD, Kalra A, Surafel GK, Thomas G, Hawkins ES, Svensson LG.

EBioMedicine. 2020; .

SARS-CoV-2 and Pulmonary Embolism: who stole the platelets?

Tran M, Sheth C , Bhandari R Cameron SJ, Hornacek D.

Thrombosis Journal. 2020; .

National trends and outcomes for extra-corporeal membrane oxygenation use in high-risk pulmonary embolism.

Elbadawi A, Mentias A, Elgendy IY, Mohamed AH, Syed MH, Ogunbayo GO, Olorunfemi O, Gosev I, Prasad S, Cameron SJ

Vascular medicine.. 2019 June 24 (3):230-233. Epub 03/05/2019.

Platelet-derived ?2M regulates monocyte inflammatory responses

Hilt ZT, Pariser DN, Ture SK, Mohan A, Quijada P, Asante A, Cameron SJ, Sterling JA, Merkel AR, Johanson AL, Jenkins JL, Small EM, McGrath KE, Palis J, Elliott MR, Morrell CN.

JCI Insight. 2019; .

Acetylcholine inhibits platelet activation

John A Bennett, Sara K Ture, Rachel A Schmidt, Michael A Mastrangelo, Scott J Cameron, Lara E Terry, David I Yule, Craig N Morrell, and Charles J Lowenstein.

Journal of Pharmacology and Experimental Therapeutics. 2019; 369(2): 182-187.

A Sex-Specific Switch in Platelet Receptor Signaling Following Myocardial Infarction

Beom Soo Kim, David A. Auerbach, Hamza Sadhra, Frederick S. Ling, MD , Sandra Toth, Amy Mohan, Sara Tura, Ilan Goldenberg, David Q. Rich, and Scott J. Cameron.

biorxiv (interim). 2019; .

The Impact of a Pulmonary Embolism Response Team on the Efficiency of Patient Care in the Emergency Department

Wright C, Elbadawi A, Chen Y, Patel D, Van Galen J, Mazzillo J, Acquisto N, Delehanty J, Pietropaoli A, Trawick D, Cameron P, Gosev I, Cameron SJ.

Journal of Thrombosis and Thrombolysis. 2019; .

Chronic Thromboembolic Pulmonary Hypertension is a Clot You Cannot Swat

Bishop GJ, Gorski J, Lachant, Cameron SJ.

Journal of Vascular Surgery (Cases and Innovative Techniques). 2019; 17(5(4)): 402-405.

Changes in triggering of ST-elevation myocardial infarction by particulate air pollution in Monroe County, New York over time: a case-crossover study

Wang M, Hopke PK, Masiol M. Thurston SW, Cameron SJ, Ling F, van Wijngaarden E, Croft D, Squizzato S, Thevenet-Morrison K, Chalupa D, Rich DQ.

Environmental Health. 2019; .

Lights Out: An Unusual Case of Amaurosis Fugax

Parsons, MR; Stoner, MC; Doyle, A; Mix, D; Cameron, SJ.

American Journal of Medicine. 2018; 131(2)(2): e39-e42.

Asymptomatic Hypotension in a Patient with Catheter-related Right Atrial Thrombus

Davis HE, Lu M, Cameron SJ, Bodkin R.

Western Journal of Emergency Medicine. 2018; 2(1).

The Impact of a Multi-Specialty Team for High Risk Pulmonary Embolism on Resident and Fellow Education

Ayman Elbadawi, Colin Wright, MD Dhwani Patel, Yu Lin Chen, Justin Mazzillo, Pamela Cameron, Geoffrey D. Barnes, and Scott J. Cameron.

Vascular Medicine. 2018; 23(4): 372-376.

Conduction Dysfunction Then It's Expunction: Giant Cell Myocarditis Manifesting as Arrhythmias and Heart Block

Conrad Gleber, Ayhan Yoruk, M.D, Luke Eastburg, Bruce I. Goldman, and Scott J. Cameron.

American Journal of Medicine. 2018; S0002-9343(19).

Publication Link

Cameron SJ, Mix D, Ture S, Schmidt R, Mohan A, Pariser D, Stoner M, Shah P, Chen L, Zhang H, Field DJ, Modjeski KL, Toth S, Morrell CN.

Hypoxia and Ischemia Promote a Maladaptive Platelet

Do elevated blood levels of omega-3 fatty acids modify effects of particulate air pollutants on fibrinogen?

Daniel Patrick Croft, Robert Block,Scott Cameron, Kristin Evans, Charles Lowenstein, Frederick Ling, Wojciech Zareba, Philip Hopke, Mark Utell, Sally Thurston, Kelly Thevenet-Morrison, David Rich.

Air Quality, Atmosphere & Health. 2018; .

Platelet CD36 signaling through ERK5 promotes Caspase-Dependent Procoagulant Activity and Fibrin Deposition in Vivo

Moua Yang, Andaleb Kholmukhamedov, Marie L. Schulte, Brian C Cooley, Na'il O Scoggins, Jeremy P Wood, Scott Cameron, Craig N Morrell, Shawn Jobe, and Roy L. Silverstein.

Blood Advances. 2018; .

Medical management of Acute Aortic Syndromes

Morris J, Mix D, Cameron SJ.

Current Treatment Options in Cardiovascular Medicine. 2017; 19 (4)(29).

Platelet CD36 Induces ERK5 Activation through a Redox-Regulated Signaling Pathway to Promote a Prothrombotic Phenotype.

Yang M, Vasque-Vivar JM, Cameron SJ, Morrell CN, Silverstein R.

Blood. 2017; 129(21): 2917-2927.

A young man with acute ST-elevation myocardial infarction.

Miller EO, Krishnamoorthy VK, Ling, FSK, Chaturvedi A, Cameron SJ.

British Medical Journal. 2017; 357(2198).

Platelet factor 4 increases bone marrow B cell development and differentiation.

Field, DJ, Aggrey-Amble, AA, Blick, SK, Ture, SK, Johanson, A, Cameron, SJ, Roy, S, Morrell, CN.

Immunologic Research. 2017; .

Cancer and Thrombotic Risk: The Platelet Paradigm

Lee, EC and Cameron, SJ.

Frontiers in Cardiovascular Medicine. 2017; 7(4:67).

Glutamate Receptor Interacting Protein 1 Mediates Platelet Adhesion and Thrombus Formation.

Modjeski KL, Ture SK, Field DJ, Cameron SJ, Morrell CN.

PLoS One. 2016; 11(9).

Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion.

Cameron SJ, Ture SK, Mickelsen D, Chakrabarti E, Modjeski KL, McNitt S, Seaberry M, Field DJ, Le NT, Abe JI, Morrell CN

Circulation.. 2015 July 7132 (1):47-58. Epub 05/01/2015.

Treacherous Travelers: Emboli.

Cameron SJ, Laskurain E, Holcman K, Richeson JF, Mieszczanska H

The American journal of medicine.. 2015 July 128 (7):695-8. Epub 03/05/2015.

Vascular Medicine: The Eye Cannot See What the Mind Does Not Know.

Cameron SJ

Journal of the American College of Cardiology.. 2015 June 3065 (25):2760-3. Epub 1900 01 01.

Family Business of Aortopathies.

Fernandez G.; Cameron S.; Nayda J.; Cove C.; Waits B.

Am J Med. 2015; 128(11): e13-5.

A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease.

Cameron SJ, Daimee U, Block RC

European review for medical and pharmacological sciences.. 2015 19 (14):2628-2633. Epub 1900 01 01.

A Novel Anti-Inflammatory Effect for High Density Lipoprotein.

Cameron SJ, Morrell CN, Bao C, Swaim AF, Rodriguez A, Lowenstein CJ

PloS one.. 2015 10 (12):e0144372. Epub 12/17/2015.

Breathtaking: Platypnea-orthodeoxia syndrome.

Holcman K, Cameron SJ, Laskurain E, Massey HT, Trawick DR, Mieszczanska H

The American journal of medicine.. 2014 June 127 (6):491-3. Epub 03/06/2014.

Ambient fine particulate air pollution triggers ST-elevation myocardial infarction, but not non-ST elevation myocardial infarction: a case-crossover study.

Gardner B, Ling F, Hopke PK, Frampton MW, Utell MJ, Zareba W, Cameron SJ, Chalupa D, Kane C, Kulandhaisamy S, Topf MC, Rich DQ

Particle and fibre toxicology.. 2014 January 211 :1. Epub 01/02/2014.

Severe coronary disease in an adult considered at low cardiovascular disease risk with a healthy lifestyle.

Cameron SJ, Block RC, Richeson JF

Journal of clinical lipidology.. 2013 7 (5):526-30. Epub 05/28/2013.

Regulation of blood flow by aspirin following muscle ischemia.

Cameron SJ, Goulopoulou S, Weil BR, Kanaley JA

European review for medical and pharmacological sciences.. 2012 February 16 (2):143-50. Epub 1900 01 01.

High-density lipoprotein metabolism and endothelial function.

Lowenstein CJ, Cameron SJ

Current opinion in endocrinology, diabetes, and obesity.. 2010 April 17 (2):166-70. Epub 1900 01 01.

Aldosterone activates endothelial exocytosis.

Jeong Y, Chaupin DF, Matsushita K, Yamakuchi M, Cameron SJ, Morrell CN, Lowenstein CJ

Proceedings of the National Academy of Sciences of the United States of America.. 2009 March 10106 (10):3782-7. Epub 02/17/2009.

Interference in clinical chemistry assays by the hemoglobin-based oxygen carrier, Hemospan.

Cameron SJ, Gerhardt G, Engelstad M, Young MA, Norris EJ, Sokoll LJ

Clinical biochemistry.. 2009 February 42 (3):221-4. Epub 11/11/2008.

Pseudohyponatremia in a patient with HIV and hepatitis C coinfection.

Garibaldi BT, Cameron SJ, Choi M

Journal of general internal medicine.. 2008 February 23 (2):202-5. Epub 11/10/2007.

A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes.

Cameron SJ, Sokoll LJ, Laterza OF, Shah S, Green GB

Clinica chimica acta; international journal of clinical chemistry.. 2007 February 376 (1-2):168-73. Epub 10/02/2006.

Antibody to human leukocyte antigen triggers endothelial exocytosis.

Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, Wasowska BA, Baldwin WM, Pober JS, Lowenstein CJ

Proceedings of the National Academy of Sciences of the United States of America.. 2007 January 23104 (4):1301-6. Epub 01/17/2007.

Mechanisms initiating integrin-stimulated flow recruitment in arteriolar networks.

Frame MD, Rivers RJ, Altland O, Cameron S.

J Appl Physiol. 2007; 102(6): 2279-87.

Assessment of BNP and NT-proBNP in emergency department patients presenting with suspected acute coronary syndromes.

Cameron SJ, Green GB, White CN, Laterza OF, Clarke W, Kim H, Sokoll LJ

Clinical biochemistry.. 2006 January 39 (1):11-8. Epub 12/05/2005.

Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research.

Derr RL, Cameron SJ, Golden SH

European journal of epidemiology.. 2006 21 (3):217-26. Epub 1900 01 01.

HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.

Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K, Baldwin WM, Lefer DJ, Lowenstein CJ

Circulation research.. 2005 June 1096 (11):1185-92. Epub 05/19/2005.

Dysprealbuminemic hyperthyroxinemia in a patient with hyperthyroid graves disease.

Cameron SJ, Hagedorn JC, Sokoll LJ, Caturegli P, Ladenson PW

Clinical chemistry.. 2005 June 51 (6):1065-9. Epub 04/15/2005.

Cardiac biomarkers in renal disease: the fog is slowly lifting.

Cameron SJ, Green GB

Clinical chemistry.. 2004 December 50 (12):2233-5. Epub 1900 01 01.

Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patients.

Laterza OF, Cameron SJ, Chappell D, Sokoll LJ, Green GB

Clinica chimica acta; international journal of clinical chemistry.. 2004 October 348 (1-2):163-9. Epub 1900 01 01.

Activation of big MAP kinase 1 (BMK1/ERK5) inhibits cardiac injury after myocardial ischemia and reperfusion.

Cameron SJ, Itoh S, Baines CP, Zhang C, Ohta S, Che W, Glassman M, Lee JD, Yan C, Yang J, Abe J

FEBS letters.. 2004 May 21566 (1-3):255-60. Epub 1900 01 01.

Differential role of MEK5alpha and MEK5beta in BMK1/ERK5 activation.

Cameron SJ, Abe J, Malik S, Che W, Yang J

The Journal of biological chemistry.. 2004 January 9279 (2):1506-12. Epub 10/28/2003.

Regulation of epidermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase1/ERK5 but not ERK1/2 kinase activation.

Cameron SJ, Malik S, Akaike M, Lerner-Marmarosh N, Yan C, Lee JD, Abe J, Yang J

The Journal of biological chemistry.. 2003 May 16278 (20):18682-8. Epub 03/12/2003.

Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance.

Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW

The Journal of biological chemistry.. 2001 July 13276 (28):25889-93. Epub 05/07/2001.


Cardiology Consult Manual (2018)

Chapter: Vascular Medicine

Authors: Scott J. Cameron and Doran MIx

Publisher: Springer 2018

Cardiology Consult Manual (2018)

Chapter: Pulmonary Embolism

Authors: Hanna Mieszczanska and Scott J. Cameron

Publisher: Springer 2018


UR Medicine Cardiology

2400 Clinton Ave So, Bldg G, Suite 110
Rochester, NY 14618